Clinical trials: Keratoconjunctivitis Sicca
Dry Eye
Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)
The objective of this study is to compare the safety and efficacy of YP-P10 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05467293
- Testing
- 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 257 people
- Sponsor
- Yuyu Pharma, Inc.
Dry Eye Syndromes
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye
The purpose of this study is to assess the safety and effectiveness of SI-614 solution compared with placebo solution in treating patients with dry eye
- Trial name
- NCT01558999
- Testing
- High concentration SI-614, Low concentration SI-614, Vehicle
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Seikagaku Corporation
Dry Eye
An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication.
- Trial name
- NCT06439394
- Testing
- Optive MEGA-3 (OM3)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Dry Eye Syndromes
Pilot Study of TearCare System - Long-Term Extension
The objective of the study is to evaluate the long-term clinical utility, safety, and effectiveness of re-treatment with the TearCare™ System in adult patients with dry eye syndrome who had previously been treated with the…
- Trial name
- NCT03804502
- Testing
- TearCare
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye Syndrome
Safety and Tolerability of Artificial Tears in Dry Eye Subjects
The safety and tolerability of two new artificial tears will be compared to a currently-available artificial tear in subjects with dry eye. Each subject will receive all three products in a randomly assigned order.
- Trial name
- NCT00932477
- Testing
- Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Allergan
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
- Trial name
- NCT06370039
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Invirsa, Inc.
Sjogren Syndrome
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
- Trial name
- NEPTUNUS-1 (NCT05350072)
- Testing
- VAY736
- Where
- 77 sites in United States, Austria and 16 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease
The purpose of this study is to evaluate the clinical effectiveness and tolerability of SYSTANE® Complete in adult patients with dry eye disease.
- Trial name
- NCT03492541
- Testing
- Propylene glycol-based eye drops
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 134 people
- Sponsor
- Alcon Research
Dry Eye
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects…
- Trial name
- NCT03916042
- Testing
- Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Keratoconjunctivitis Sicca
A Study Of Tasocitinib In Dry Eye Subjects
This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease.
- Trial name
- NCT01226680
- Testing
- Tasocitinib, vehicle for Tasocitinib
- Sponsor
- Pfizer
Dry Eye Disease, Ocular Surface Disease
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF
This is a phase I study evaluating safety and tolerability of PRO-229 ophthalmic solution through he incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), incidence of chemosis, and changes in…
- Trial name
- NCT06370585
- Testing
- PRO-229, Lagricel® Ofteno PF
- Where
- Mexico
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Post Menopausal Dry Eye Subjects
Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye
To evaluate the efficacy of Systane Ultra in post menopausal women with dry eye.
- Trial name
- NCT01105910
- Testing
- Systane Ultra Lubricant Eye Drops, Sensitive Eyes Eye Drops (Bausch & Lomb)
- Volunteers
- 70 people
- Sponsor
- Alcon Research
Sjögren's Disease
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection…
- Trial name
- NCT07737743
- Testing
- DDY391
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndromes
Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease
The purpose of this clinical Study is Tisporin Eye Drops 0.05%(Cyclosporine ophthalmic solution) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12 weeks after treatment, each treatment group…
- Trial name
- HL_TSPR_302 (NCT02229955)
- Testing
- Cyclosporine ophthalmic solution
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Dry Eye
A Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease
A Double-Masked, Randomized, Parallel Group, Non-Inferiority Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease
- Trial name
- NCT07593885
- Testing
- Artelac® Complete MDO® Eye Drops, VISMED® MULTI Eye Drops
- Where
- 12 sites in Germany
- Volunteers
- 160 people
- Sponsor
- Dr. Gerhard Mann chem.-pharm. Fabrik GmbH
Sjogren's Syndrome
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525).
- Trial name
- TWINSS Extn (NCT04541589)
- Testing
- Iscalimab
- Where
- 62 sites in United States, Argentina and 21 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye
Evaluation of safety and efficacy of PL9643 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT04268069
- Testing
- PL9643 Ophthalmic Solution
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- ORA, Inc.
Dry Eye Disease, Endothelial Cell
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
- Trial name
- NCT06329661
- Testing
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Where
- 6 sites in United States
- Volunteers
- 204 people
- Sponsor
- Novaliq GmbH
Dry Eye Syndrome (DES)
Evaluation of a Novel Ocular Lubricating Eye Drop
The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye.
- Trial name
- DRAGON (NCT07593404)
- Testing
- Part 2 ABR2 At least twice a day for 28 days, Part 1: ABR2 single dose in one eye
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Pleryon Therapeutics (Hangzhou) Limited